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Background: Angiotensin receptor blockers (ARBs) are reported to provide direct protection to many organs by
controlling inflammation and decreasing oxidant stress in patients without arteriosclerosis. This study aimed to
evaluate (1) whether an ARB (candesartan) decreases values for inflammatory parameters in hypertensive patients
with type 2 diabetes mellitus of long duration accompanied by arteriosclerosis and (2) whether there any
predictors of which patients would receive the benefits of organ protection by candesartan.
Methods: We administered candesartan therapy (12 mg daily) for 6 months and evaluated whether there was
improvement in serum inflammatory parameters high molecular weight adiponectin (HMW-ADN), plasminogen
activator inhibitor-1 (PAI-1), highly sensitive C-reactive protein (Hs-CRP), vascular cell adhesion molecule-1 (VCAM-1)
in serum and urinary-8-hydroxydeoxyguanosine (U-8-OHdG). We then analyzed the relationship between the
degree of lowering of blood pressure and inflammatory factors and the relationship between pulse pressure
and inflammatory factors. Finally, we analyzed predictive factors in patients who received the protective benefit
of candesartan.
Results: After 6 months of treatment, significant improvements from baseline values were observed in all patients
in HMW-ADN and PAI-1 but not in Hs-CRP, VCAM-1 and U-8-OHdG. Multilinear regression analysis was performed
to determine which factors could best predict changes in HMW-ADN and PAI-1. Changes in blood pressure were
not significant predictors of changes in metabolic factors in all patients. We found that the group with baseline
pulse pressure <60 mmHg had improved HMW-ADN and PAI-1 values compared with the group with baseline
pulse pressure ≥ 60 mmHg. These results suggest that pulse pressure at baseline could be predictive of changes in
HMW-ADN and PAI-1.
Conclusions: Candesartan improved inflammatory parameters (HMW-ADN and PAI-1) in hypertensive patients
with type 2 diabetes mellitus of long duration independent of blood pressure changes. Patients with pulse
pressure <60 mmHg might receive protective benefits by candesartan.
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Table 1 Baseline data on study subjects
N 56
Sex (M/F) 46/10 (82.1%)
Age (y) 60.84
BMI (kg/m2) 25.07
Blood pressure(SBP/DBP) (mmHg) 138 (9.67)/78.6 (11.5)
Dulation (y) 15.47 (10.67)
Laboratory data
HbA1c (%) 6.87 (0.68)
FPG (mg/dl) 151.7 (47.5)
LDL-C (mg/dl) 109.7 (25.3)
HDL-C (mg/dl) 55.7(12.8)
Triglycerides (mg/dl) 150(83.0)
Creatinine (mg/dl) 0.80 (0.18)






F, female; M, male, BMI, Body-mass index; HbA1c, glycated hemoglobin; FPG,
fasting plasma glucose; LDL-C, Low density lipoprotein-cholesterol; HDL-C,
High density lipoprotein-cholesterol; OHA, oral hypoglycemic agent, *P<0.05.
Data are expressed as means±s.d. or n and%.
Sakamoto et al. Cardiovascular Diabetology 2012, 11:118 Page 2 of 9
http://www.cardiab.com/content/11/1/118Background
Almost half of type 2 diabetic patients are reported
to have hypertension during their lifetime [1], and the
coexistence of hypertension and diabetes mellitus espe-
cially increases the risk of cardiovascular events. More-
over, much of this excess risk is attributable to
coexistent hypertension [2]. Treatment of hypertension
in patients with type 2 diabetes mellitus of short dur-
ation has been shown to reduce cardiovascular events
[3,4]. Therefore, in addition to glycemic control, the
treatment of hypertension is important in preventing
cardiovascular events. On the other hand, unexpect-
edly, the ACCORD BP study recently performed in
patients with type 2 diabetes of long duration (average
10 years) showed that strict blood pressure control
failed to reduce cardiovascular events [5]. But a
detailed examination of that result, which included in-
vestigation of inflammatory parameters, has not been
performed.
Angiotensin receptor blockers (ARBs) are regarded
as first line therapy for hypertensive patients with type 2
diabetes mellitus [6,7]. In addition to their antihyper-
tensive effects, results of a multi-center trial showed
that ARBs had a role in preventing the development
of type 2 diabetes [8]. Also, ARBs have been shown
to protect many organs by controlling inflammation
[9-12] and decreasing oxidant stress [13] in hyperten-
sive patients without arteriosclerosis. But there is little
evidence that ARBs have a positive effect in patients
with advanced arteriosclerosis, such as those with type 2
diabetes mellitus of long duration accompanied by
hypertension as were the patients in the ACCORD BP
study. Furthermore, pulse pressure increases during
the process of arteriosclerosis. It has been reported
that pulse pressure is not only a predictor of cardiovas-
cular events [14,15], but also is an independent pre-
dictor of new-onset diabetes in high-risk hypertensive
patients [16].
In this study, we administered an ARB (candesartan:
only sartan which can use for chronic heart failure
patients in Japan) to hypertensive patients with type 2 dia-
betes mellitus and evaluated whether there was improve-
ment in the following inflammatory parameters: high
molecular weight adiponectin (HMW-ADN), plasminogen
activator inhibitor-1 (PAI-1), highly sensitive C-reactive
protein (Hs-CRP), vascular cell adhesion molecule-1
(VCAM-1) and urinary 8-hydroxydeoxyguanosine (U-8-
OHdG). We then analyzed the relationship between the
degree of lowered blood pressure and values for inflam-
matory factors and the relationship between pulse pres-
sure and pulse wave velocity (PWV), which are index
parameters of arteriosclerosis. Finally, we analyzed pre-
dictors of patients who would receive benefit from can-
desartan by protecting their organs.Methods
Participants
This was a prospective study. Patients were targeted for
enrollment among hypertensive patients with type 2 dia-
betes mellitus who regularly attended the Jikei University
School of Medicine affiliated hospital for treatment.
We enrolled 56 patients (46 males and 10 females,
25–75 years old, average 60) who had hypertension
(defined as diastolic blood pressure [DBP] ≧80 mmHg
or systolic blood pressure [SBP] ≧130 mmHg, average
138/79) or were taking antihypertensive medicine
(Table 1). Patients with secondary hypertension were
excluded, as were patients with impaired liver function
defined as plasma aminotransferase (or aspartate
aminotransferase) over 39 mUml (normal values: 11–39
mUml) and alanine aminotransferase over 34 mUml
(normal values: 11–34 mUml) or impaired kidney func-
tion (defined as serum creatinine level over 1.3 mg per
100 ml (normal values: 0.6–1.3 mg per 100 ml). Patients
with unstable cardiovascular conditions (e.g., New York
Heart Association class I–IV congestive heart failure or
a history of myocardial infarction or stroke) or cerebro-
vascular incidents within 6 months of study enrollment
were also excluded. Women who were pregnant, lactat-
ing, or who might become pregnant due to inadequate
contraceptive precautions were also excluded. Patients
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sartan were also not included in the study.
Patients were administered 12 mg candesartan daily at
the same time for a duration of 6 months. At the begin-
ning of the study, if patients were taking an ARB
or ACE-I, that drug was replaced with 12 mg cande-
sartan. Antihyperglycemic drugs were not changed dur-
ing this study.
The study protocol was approved by the institutional
review board at Jikei University School of Medicine
and conducted in accordance with the Declaration of
Helsinki and its amendments. After a full explanation of
the study, all patients gave written informed consent.
Assessment of participants
Before starting the study, all patients underwent an ini-
tial screening assessment that included a medical history
and physical examination. We evaluated patients at the
start of the study to establish baseline values, then again
after the 6th month of treatment. Parameters were as fol-
lows: body weight, body mass index (BMI), SBP, DBP,
PWV, HbA1c, fasting plasma glucose (FPG), HMW-
ADN, PAI-1, Hs-CRP, VCAM-1 and U-8-OHdG.
To evaluate tolerability to candesartan, all adverse
events were recorded. All plasmatic parameters were
measured after a 12-h overnight fast. In all cases, venous
blood samples were taken between 800 and 900 h. We
used plasma obtained by the addition of Na2-EDTA
(1mgml_1) and centrifuged at 3000 g for 15 min at 4°C.
All measurements were performed in a central laboratory.
BMI was calculated as weight (kg) divided by the
square of height (m). Height and weight were deter-
mined using a standard scale (SYSTEM 502, TANITA,
Tokyo, Japan). Aortic PWV measurements using the
right carotid and right femoral arteries were performed
with the patient in a supine position after resting at least
5 min. A Vasera VS-1500A System (Fukuda Denshi,
Tokyo, Japan) device was used at each site. All personnel
were trained and certified to take blood pressure mea-
surements from the right arm with a Tyco aneroid
sphygmomanometer using American Heart Association
standards and to perform the aortic PWV measure-
ments. Blood pressure measurements were obtained
from the patients’ right arm while they were in a seated
position, using a standard sphygmomanometer (AD-
VANCE BP-203RVIIIC/D, OMRON colin, Tokyo, Japan)
(Korotkoff I and V) with an appropriately sized cuff. Fur-
thermore, the same investigator measured patients’
blood pressure at each visit, always in the morning and
after the patient had rested for at least 10 min in a quiet
room. Three successive blood pressure readings were
obtained at 1-min intervals, and the mean of the three
readings was calculated. HbA1c level was measured
by a high-performance liquid chromatography method(HLC723-G9, TOSOH, Tokyo, Japan; normal values
Japan Diabetes Society: 4.4–5.8%), with intra- and inter-
assay coefficients of variation (CsV) of 1%. Plasma glucose
was assayed by the glucose-oxidase method (GA08II,
A&T, Yokohama, Japan) with intra- and inter-assay CsV
of 0.8%.
Plasma HMW-ADN level was determined using an
CLEIA (chemiluminescent enzyme immunoassay; Fuji
Rebio,Tokyo, Japan). Plasma VCAM-1 level (normal
values 277-836 ng/ml) was determined using an ELISA
(enzyme-linked immunosorbent assay; R&D Systems.
Inc. Minneapolis, U.S.A). Plasma PAI-1level (normal
values ≤50 ng/ml) were determined using a LPIA (latex
photometric immunoassay; Mitsubishi Chemical Medi-
ence. Tokyo, Japan). The U-8-OHdG level (normal
values: 6.1-16.3 ng/mg · cr) was measured using HPLC
(high performance liquid chromarography; Mitsubishi
Chemical Medience. Tokyo, Japan). Plasma hs-CRP level
(normal values ≤0.3 mg/dl) was measured using the latex
agglutination nephelometry method (Siemens Healthcare
Diagnostics Inc. Marburg, Germany).
Statistical analysis
Statistical analysis of data was performed using the Stat-
istical Package for Social Sciences software, version 19.0
(SPSS, Chicago, IL, USA). The data are presented as the
mean±s.e. For all statistical analyses, P<0.05 was consid-
ered statistically significant.
Results
Characteristics of study sample
Fifty-six patients were enrolled in the study and of these
46 completed the study. The reason for premature with-
drawal was lost-to-follow-up. The characteristics of the
patient population upon entering the study and the anti-
diabetic agents taken before and during the study are
shown in Table 1.
Patient data at baseline prior to and after the 6 months
of the study (Table 2)
Significant improvements from baseline values were
observed in both SBP and DBP after 6 months (SBP,
*P=0.002; **DBP, P=0.005, Table 2 and Figure 1). HbA1c
and FPG values did not change from baseline after the
6-month treatment period (Table 2 and Figure 2). By
correlation analysis we observed a significant correlation
between pulse pressure and PWV (CC=0.494, P=0.004).
Furthermore, multiple regression analysis showed that
pulse pressure was independent of age and BMI (Table 3
and Figure 3). Significant improvements in baseline
values for HMW-ADN and PAI-1 were recorded in all
patients after 6 months of treatment (*P<0.05). Hs-CRP,
VCAM-1 and U-8-OHdG values did not decrease
from baseline after 6 months of candesartan treatment
(Figure 4).
Table 2 Patient data at baseline and after 6 months
study period
Baseline After 6 months
N 56 46
Dropped out N/A 10







Duration (y) 15.47 (10.67) 16.54 (10.88)
Laboratory data
HbA1c (%) 6.87 (0.68) 6.86 (0.93)
FPG (mg/dl) 151.7 (47.5) 137.02 (55.22)
HWM-AND (μg/ml) 4.89 (3.16) 5.87 (3.90)*
PAI-1 (mg/dl) 27.63 (16.28) 23.17 (7.43)*
VCAM-1 (mg/dl) 715.09 (173.70) 712.06 (196.04)
U-8-OHdG (pg/ml) 11.28 (3.22) 11.65 (3.15)
Hs-CRP (mg/dl) 0.093171 (0.015391) 0.099737 (0.015174)
Blood glucose lowering treatment
Insulin only 11 10
Insulin+OHA 7 7
OHA 32 24
Diet only 6 5
BMI, body mass index; HbA1c, glycated hemoglobin A1c; FPG, fasting plasma
glucose; HMW-ADN, high molecular weight-adiponectin; PAI-1, plasminogen
activator inhibitor-1; VCAM-1, vascular cell adhesion molecule-1; U-8-OHdG,
urinary-8-hydroxydeoxyguanosine; Hs-CRP, high-sensitivity C-reactive protein;
OHA, oral hypoglycemic agent. Data are expressed as means±s.d. or n and%.
*P<0.05.
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blood pressure changes
Correlation analysis was performed to establish which
factors could best predict changes in patients’ HMW-
ADN and PAI-1 values. Changes in blood pressure were
not significant predictors of changes in the following
metabolic factors in any of the patients: ΔSBP vs.


























Figure 1 Systolic blood pressure (SBP) and diastolic blood
pressure (DPB) pre- and post-study (6 mo). *P+0.002 for SBP and
**P=0.005 for DBP.ΔHMW-ADN CC=0.007, P=0.963 (Figure 5b), ΔSBP vs.
ΔPAI-1 CC=0.009, P=0.953 (Figure 5c), and ΔDBP vs.
ΔPAI-1 CC=0.023, P=0.885 (Figure 5d).
Relationship between HMW-ADN and PAI-1 changes and
pulse pressure
HMW-ADN and PAI-1 values improved in patients
grouped according to before-study pulse pressure
< 60 mmHg compared with those grouped according to
before-study pulse pressure ≥ 60 mmHg (*P<0.01,
**P<0.05, Figure 6).
Discussion
Although the antihypertension drug candesartan has
been reported to control inflammation [17,18], there is
little evidence about differences in effect by candesarton
among each inflammatory parameter and what factors
contribute to the differences. Moreover, there is the
question of whether there are anti-inflammatory effects
by candesartan in patients with advanced arteriosclerosis
such as those with type 2 diabetes mellitus of long
duration accompanied by hypertension. In this study, we
analyzed the predictors showing which patients would
receive the benefit of organ protection by candesartan.
HMW-ADN and PAI-1
Although both HMW-ADN and PAI-1 values had
improved significantly at the end of the study period,
there was no relationship between these parameters and
SBP and DBP at baseline nor did changes in SPB and
DBP have any relationship between changes in these
parameters. These results might indicate that candesar-
tan improved these parameters directly and not through
changes in blood pressure.
HMW-ADN is secreted from adipose tissue and has a
protective effect against cardiovascular disease [19]. It
was reported that HMW-ADN values change not only
in the advanced stage of arteriosclerosis such with
arteriosclerosis obliterans [20] but that HMW-AND is
an independent prognostic factor [21].
PAI-1 is the primary physiological inhibitor of en-
dogenous fibrinolysis that acts via inhibition of the tissue
plasminogen activator (tPA) and the urokinase type acti-
vator (uPA), often leading to fibrin accumulation in
basement membranes and interstitial tissues. Elevated
plasma PAI-1 has been demonstrated in various sub-
groups as an important feature of type 2 diabetes and
metabolic syndrome [22]. Plasma levels of PAI-1 were
reported to predict the occurrence of a first acute
myocardial infarction and reinfarction [23]. Recently, the
BARI 2D Trial of subjects with a mean duration of
diabetes mellitus of 10.4 years with stable coronary
artery disease reported that for the older patients redu-
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results of our study appear to support these results.
Although the mean duration of diabetes mellitus in
our study was over 15 years, HMW-ADN and PAI-1
values were reduced after patients received 12 mg can-
desartan o.d. for 6 months. This result might partially
explain the protective effect of candesartan therapy
against cardiovascular disease in hypertensive patients
with type 2 diabetes mellitus.
On the other hand, there is evidence that pulse pres-
sure is an index parameter of arteriosclerosis. Pulse pres-
sure is a marker of arteriosclerosis that can be measured
simply. It is correlated with IMT and PWV, and an
increase in pulse pressure has been reported to be asso-
ciated with risk of onset of coronary artery disease
[25,26]. It is a predictor of overall mortality in elderly
persons [27]. It was also reported that pulse pressure
could be a predictive factor of a cardiovascular event in
persons with diabetes mellitus [28]. In healthy subjects,
pulse pressure over 55 mmHg is associated with risk of
a cardiovascular event [29]. Another study showed that
pulse pressure over 70 mmHg presented a risk in elderly
persons [30]. Among our study population, in those
with type 2 diabetes mellitus of long duration, a correl-
ation between pulse pressure and PWV was observed
(CC=0.494,P=0.004). Multiple linear regression analysis
suggested that pulse pressure had a relationship to PWV






PP, pulse pressure; BMI, body mass index.We therefore focused attention on the relationship be-
tween changes in inflammatory parameters and changes in
pulse pressure. Prior to the study, we divided patients into
2 groups, group A with high pulse pressure (66.0 mmHg
± 0.8) and group B with low pulse pressure (52.0 mmHg
± 0.8), and examined the rates of improvement in blood
pressure, HMW-ADN, and PAI-1. In the total patient
population, the median pulse pressure was 60.0 mmHg±1.4.
Interestingly, a significant improvement in HMW-
ADN and PAI-1 was observed in the group with pulse
pressure ≧60 mmHg (group A) compared with the
group with pulse pressure <60 (group B). Findings
were as follows: ΔSBP: average =−9.20, P value=0.048;
ΔDBP: average =−6.61, P value=0.08; ΔAND: average
= group A 2.3 and group B 0.052 μg/ml, P value=0.005;
PAI-1: average =group A −10.1 and group B −0.48 ng/ml,
P value =0.012. These results suggest that diabetic
patients with comparatively low pulse pressure indicat-
ing less advanced arteriosclerosis may receive benefits of
improvement in inflammatory parameters such as HMW-















Figure 3 Single correlation analysis of pulse pressure (PP) and



















































































Figure 4 Changes from baseline of inflammatory parameters after 6 months of treatment with candesartan (*P<0.05). HMW-ADN, high
molecular weight adiponectin; PAI-1, plasminogen activator inhibitor-1; VCAM-1, vascular cell adhesion molecule-1; U-8-OHdG, urinary
8-hydroxydeoxyguanosine.
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Hs-CRP, VCAM-1 and U-8-OHdG values did not
change during this study. Also, there were no relation-
ships between blood pressure and pulse pressure
changes and Hs-CRP, VCAM-1 and U-8-OHdG.
In this study, no improvement in Hs-CRP was observed
because of the following reasons. It has been reported
that Hs-CRP levels are increased in patients with arterio-
sclerosis and other diseases that cause blood flow disturb-
ance, and that Hs-CRP can be used as a predictor of
cardiovascular events. On the other hand, it has also
been reported that Hs-CRP is increased in patients with
obesity and diabetes, and could be decreased by certain
antidiabetic drugs. The subjects of this study had a long
history of diabetes, and drugs were used in most subjects.
Indeed, the Hs-CRP levels were likely below detection
level in almost half of the subjects before the commence-
ment of the study, and this might contribute to the lack
of improvement of Hs-CRP. The reason might be that
VACM-1 reflects early vascular endothelial dysfunction,
so it increases from the onset of hypertension or diabetes
mellitus [31]. The histories of diabetes and hypertension
varied among the study population. Also, the study dur-
ation was too short to recognize changes in U-8-OHdG,as it could be expected to take longer for U-8-OHdG to
change than the other factors evaluated. Moreover,
although past clinical studies have suggested that ARB
would have antioxidative and anti-inflammatory effects,
most of the studies were performed in subjects that were
not being treated with antihypertensive drugs. In this
study, patients undergoing treatment with antihyper-
tensive drugs, such as ARB, were included, and thus the
study results might be affected by the fact that the levels
of VCAM-1 and U-8-OHdG were already within a nor-
mal range prior to commencement of the study.
Alternatively, candesartan might be less effective in
patients with advanced arteriosclerosis with regard to
Hs-CRP, VACM-1 and U-8-OHdG. This may be why the
ACCRD BP study did not find positive data for type 2
diabetic patients with hypertension from the point of
view of inflammatory parameters.
It has been reported that ARB could increase adipo-
nectin levels to a greater degree compared with calcium
channel blockers and β blockers. By contrast, it has also
been reported that ARB would have greater effects on
VACM-1, U-8-OHdG, and PAI-1, while protecting
organs, compared with calcium channel blockers in pre-
















































































Figure 5 Multilinear regression analysis of HMW-ADN and PAI-1 changes and blood pressure changes. HMW-ADN, high molecular
weight-adiponectin; PAI-1, plasminogen activator inhibitor-1; SBP, systolic blood pressure; DBP, diastolic blood pressure.
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studies, especially for patients with diabetes.
This study has limitations as single group pre-post
study, small population, the unbalance between men and
women. The results of larger clinical trials evaluating the


















Figure 6 Relationship between high molecular weight-adiponectin (H
and pulse pressure (PP).Conclusion
Candesartan improved plasma HMW-ADN and PAI-1
values but not those of plasma Hs-CRP, VACM-1 and U-
8-OHdG in hypertensive patients with type 2 diabetes
mellitus of long duration independently of blood pres-
sure changes. Patients whose pulse pressure is under

















MW-ADN) and plasminogen activator inhibitor-1 (PAI) changes
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PAI-1 by administration of candesartan.
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